BiotechTube

Zoledronic acid + Letrozole

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bone Loss

Conditions

Bone Loss, Breast Cancer

Trial Timeline

May 1, 2003 → Feb 1, 2010

NCT ID
NCT00171340

About Zoledronic acid + Letrozole

Zoledronic acid + Letrozole is a phase 3 stage product being developed by Novartis for Bone Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00171340. Target conditions include Bone Loss, Breast Cancer.

What happened to similar drugs?

16 of 20 similar drugs in Bone Loss were approved

Approved (16) Terminated (1) Active (4)
✅Reclast (ZOL446, zoledronic acid)NovartisApproved
✅zoledronic acidNovartisApproved
✅Zoledronic acidNovartisApproved
✅Disodium pamidronate + PlaceboNovartisApproved
✅Zoledronic acidNovartisApproved
✅Zoledronic acidNovartisApproved
✅PamidronateNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00171314Phase 3Completed
NCT00171340Phase 3Completed
NCT00050011Phase 3Completed

Competing Products

20 competing products in Bone Loss

See all competitors
ProductCompanyStageHype Score
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
EnzalutamideAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
MerestinibEli LillyPhase 1
21
FORTEO + PlaceboEli LillyPhase 1
29
Arzoxifene + PlaceboEli LillyPhase 3
40
TanezumabEli LillyPhase 3
40
Anastrozole + TamoxifenAstraZenecaPhase 3
40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
NilotinibNovartisPhase 1
29
Reclast (ZOL446, zoledronic acid)NovartisApproved
43
Zoledronic acidNovartisPhase 3
32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic AcidNovartisPhase 3
40
zoledronic acidNovartisPhase 1
29
Ruxolitinib continuous therapyNovartisPhase 2
39
zoledronic acidNovartisApproved
43